These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14630248)

  • 21. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases.
    Neyns B; Van Nieuwenhove Y; Aerts M; Fontaine C; Vermeij J; Schallier D; Decoster L; De Mey J; Vandenbroucke F; Hoorens A; Delvaux G; De Gréve J
    Anticancer Res; 2006; 26(1B):611-9. PubMed ID: 16739329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.
    Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M
    In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxaliplatin pharmacokinetics during a four-hour infusion.
    Kern W; Braess J; Böttger B; Kaufmann CC; Hiddemann W; Schleyer E
    Clin Cancer Res; 1999 Apr; 5(4):761-5. PubMed ID: 10213210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
    Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
    Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
    Kern W; Beckert B; Lang N; Stemmler J; Beykirch M; Stein J; Goecke E; Waggershauser T; Braess J; Schalhorn A; Hiddemann W
    Ann Oncol; 2001 May; 12(5):599-603. PubMed ID: 11432616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation.
    Merkel U; Farker K; Wedding U; Roskos M; Hippius M; Höffken K; Hoffmann A
    Int J Clin Pharmacol Ther; 2006 Mar; 44(3):128-34. PubMed ID: 16550735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
    Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
    Lévi F; Karaboué A; Etienne-Grimaldi MC; Paintaud G; Focan C; Innominato P; Bouchahda M; Milano G; Chatelut E
    Clin Pharmacokinet; 2017 Feb; 56(2):165-177. PubMed ID: 27393140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronomodulated infusion of 5-fluorouracil, folinic acid and carboplatin in colorectal cancer: a pilot study.
    Natoli C; Martino MT; Irtelli L; D'Ostilio N; Basilico L; Iacobelli S
    Anticancer Res; 1995; 15(6B):2841-2. PubMed ID: 8669875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Modeling 5-FU clearance during a chronomodulated infusion].
    Kwiatkowski F; Chevalier V; Chevrier R; Richard D; Cure H; Chollet P
    Pathol Biol (Paris); 2003 Jun; 51(4):231-3. PubMed ID: 12852999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
    Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
    J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
    Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
    Sagawa T; Tsuji Y; Takayanagi N; Hirayama Y; Sakamaki S; Chiba H; Iyama S; Oku T; Sato Y; Takahashi M; Takayama T; Niitsu Y
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):537-43. PubMed ID: 12722689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chronomodulated chemotherapy of oxaliplatin, 5-fluorouracil and folinic acid for advanced gastric cancer].
    Lu JW; Zhou ZF; Yin BJ; Liu DL; Feng JF; Zhu LJ; Pan LX
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):695-7. PubMed ID: 16438895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
    Lévi F; Zidani R; Misset JL
    Lancet; 1997 Sep; 350(9079):681-6. PubMed ID: 9291901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
    Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
    Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
    J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.